Department of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China; NHFPC Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou, 310003, China.
Cancer Lett. 2020 Apr 28;476:120-128. doi: 10.1016/j.canlet.2020.02.016. Epub 2020 Feb 16.
Hepatocellular carcinoma (HCC), the main cause of liver cancer-related death, is one of the main cancers in terms of incidence and mortality. However, HCC is difficult to target and develops strong drug resistance. Therefore, a new treatment strategy is urgently needed. The clinical application of the concept of synthetic lethality in recent years provides a new therapeutic direction for the accurate treatment of HCC. Here, we introduce the concept of synthetic lethality, the screening used to study synthetic lethality, and the identified and potential genetic interactions that induce synthetic lethality in HCC. In addition, we propose opportunities and challenges for translating synthetic lethal interactions to the clinical treatment of HCC.
肝细胞癌(HCC)是导致肝癌相关死亡的主要原因,是发病率和死亡率方面的主要癌症之一。然而,HCC 难以靶向,并且具有很强的耐药性。因此,迫切需要新的治疗策略。近年来合成致死性概念的临床应用为 HCC 的精确治疗提供了新的治疗方向。在这里,我们介绍了合成致死性的概念、用于研究合成致死性的筛选方法以及鉴定和潜在的遗传相互作用,这些相互作用在 HCC 中诱导合成致死性。此外,我们还提出了将合成致死相互作用转化为 HCC 临床治疗的机会和挑战。